ALX Oncology logo
ALX Oncology
ALXO | NASDAQ
Chart Builder DCF Calculator
$1.00
-$0.04 (-3.85%)
At close: Nov 16, 2026, 4:00 PM ET
$0.98
-$0.02 (-2.00%)
After-hours: Nov 16, 2026, 7:30 PM ET

ALX Oncology Company Profile

Company profile explained

Company Profile

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company’s lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer. It has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under phase 1b/2 trial for the treatment of breast cancer and other solid tumors; HER2 with an ADC, fam-trastuzumab deruxtecan-nxki, under phase 1 trial for the treatment of patients with breast cancer; ALX2004, under phase 1 clinical trial for treating solid tumors; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; and Sanofi with isatuximab and dexamethasone, under phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma. It has license agreements with Board of Trustees of Leland Stanford Junior University. The company was incorporated in 2015 and is headquartered in South San Francisco, California.

Key Executives

Name Position
Jason W. Lettmann Chief Executive Officer & Director
Harish Shantharam Chief Financial Officer
Athanasios Tsiatis Senior Vice President of Clinical Development
Barbara J. Klencke Chief Medical Officer
Jeff E. Knight Chief Development & Operating Officer
Lin Yeong-Liang Senior Vice President of Drug Safety & Pharmacovigilance
Lisa Sauer Senior Vice President of Regulatory Affairs & Quality Assurance
Michael Listgarten General Counsel
Shelly Wong Senior Vice President of Finance & Chief Accounting Officer
Sue Naim Senior Vice President of Clinical Operations
Venita De Almeida Vice President & Head of Research Program Development

Latest SEC Filings

Date Type Title
Oct 16, 2026 SC 13D/A [Amend] Filing
Oct 15, 2026 8-K Current Report
Aug 18, 2026 4 Filing
Aug 18, 2026 4 Filing
Aug 14, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Aug 06, 2026 10-Q Quarterly Report
Aug 06, 2026 8-K Current Report
Jul 27, 2026 SC 13G Statement of acquisition of beneficial ownership b...
Jul 06, 2026 4 Filing
Jun 30, 2026 8-K Current Report
View All SEC Filings ➞
ALX Oncology
ALX Oncology logo
Country United States
IPO Date Jul 17, 2020
Industry Biotechnology
Sector Healthcare
Employees 48
CEO Jason Lettmann

Contact Details

323 Allerton Avenue South San Francisco, California 94080 United States

Stock Details

Ticker Symbol ALXO
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001810182
CUSIP Number 00166B105
ISIN Number US00166B1052
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.